Lupin investors can look at target of 2200: Seshadri Bharathan, KSEMA Fincon Ltd

Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, in a chat with ET Now talks about Lupin.

There is a lot of institutional interest coming into Lupin as well fair visibility of the earnings also. Will that be a significant booster for this company?

If you look at the pharma space definitely yes companies which are in generic business are expected to do well because by 2012 we expect the generic business market to open up. Off patent would be around more than $130 billion and companies which are in generic business would benefit. Companies which have very strong good tie ups with the US companies for marketing will do well. So a company like Lupin would do well.

Are there any particular price targets that you would recommend?

I think Lupin investors can look at price target of around 2200 in next one years’ time.